Background and Objective: Side effects of some drugs may be useful in certain cases. In
this work, we studied the inhibitory effects on Lipases of some medications as: Folic Acid which is
taken by pregnant women, Colchicine and Febuxostat which is used as treatment of gout disease. These
cases are linked to obesity, where women (BMI ≥ 30) have twice higher odds of having an NTDaffected
pregnancy than the normal weight women, and the Gout disease frequently occurs in combination
of a Metabolic syndrome. The risk of gout increases with the increase of the mass index. In silico
studies were aimed to determine the mechanism of inhibition and different interactions for two enzymes:
Candida rugosa lipase and human pancreatic lipase.
Methods: In the first part of this study, we studied the inhibition activity of these medications on lipase
activity of Candida rugosa in vitro. Autodock vina was used for molecular docking with 50 runs and
1000 obtained solutions. The saved interactions were with His449 and Ser209 for the three molecules.
Results: The results show that these drugs have an important inhibition activity with IC50 values 0.64
mg/ml for Folic acid and 0.66 mg/ml for Febuxostat. The results of in silico show competitive, Noncompetitive
and uncompetitive inhibition for folic acid, febuxostat and colchicine respectively for two
enzymes with different repetition ratios of hydrogen bonds.
Conclusion: These observations support a higher intake of dietary folate, and febuxostat for losing
weight to decrease NTD risk and prevent hyperuricemia and recurrent gout attacks.